Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07449936 · ClinicalTrials.gov registry record · Phase 3
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
A Phase 3 study of Diabetic Macular Edema and Diabetic Macular Edema (DME), sponsored by EyePoint Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
- 3
- Study locations
NCT07449936: Recruiting Phase 3 study of Diabetic Macular Edema and Diabetic Macular Edema (DME), sponsored by EyePoint Pharmaceuticals.
NCT07449936 is a Phase 3 study of Diabetic Macular Edema and Diabetic Macular Edema (DME) that is actively recruiting participants, run by EyePoint Pharmaceuticals. The registered enrollment target is 240 participants, below the 3,791-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07449936, a Phase 3 study of Diabetic Macular Edema and Diabetic Macular Edema (DME), is actively recruiting participants, sponsored by EyePoint Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Primary Outcome
BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) letter score change from Baseline to the average of Weeks 52 and 56
Conditions Studied
Interventions
- DRUG EYP-1901
- DRUG Aflibercept (2.0 mg)
Study Locations (3)
California
- Global Research Management, Inc. - Glendale
Indiana
- Midwest Eye Institute - Carmel - Carmel
Texas
- Mt. Olympus Medical Research - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2026-02-26 |
| Est. Completion | 2028-08 |
| Phase | Phase 3 |
What NCT07449936 shows while recruiting
NCT07449936 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 3,791-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Diabetic Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which EYP-1901 is the first listed.
NCT07449936 reports a single indexed study location in California, Indiana, Texas.
Frequently Asked Questions
What is clinical trial NCT07449936 about?
NCT07449936 is a clinical study titled "COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME". This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
What is the current status of trial NCT07449936?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2026-02-26. Estimated completion is 2028-08.
What conditions does trial NCT07449936 study?
This clinical trial studies the following conditions: Diabetic Macular Edema, Diabetic Macular Edema (DME), DME.
What interventions are being tested in trial NCT07449936?
The interventions under investigation include: EYP-1901 (DRUG), Aflibercept (2.0 mg) (DRUG).
Who is sponsoring clinical trial NCT07449936?
This trial is sponsored by EyePoint Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07449936 being conducted?
This trial has 3 study locations across California, Indiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07449936's enrollment target sits among peer trials
240 19th of 63 higher than 44 of 63 other Diabetic Macular Edema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Macular Edema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
RECRUITING · Phase 3
-
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 3
-
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
ACTIVE NOT RECRUITING · Phase 3
-
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)
ACTIVE NOT RECRUITING · Phase 3
-
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI